[go: up one dir, main page]

NO20023879D0 - Partielle fettsyre-oksydasjonsinhibitorer i behandlingen av kongestiv hjertesvikt - Google Patents

Partielle fettsyre-oksydasjonsinhibitorer i behandlingen av kongestiv hjertesvikt

Info

Publication number
NO20023879D0
NO20023879D0 NO20023879A NO20023879A NO20023879D0 NO 20023879 D0 NO20023879 D0 NO 20023879D0 NO 20023879 A NO20023879 A NO 20023879A NO 20023879 A NO20023879 A NO 20023879A NO 20023879 D0 NO20023879 D0 NO 20023879D0
Authority
NO
Norway
Prior art keywords
treatment
fatty acid
heart failure
congestive heart
acid oxidation
Prior art date
Application number
NO20023879A
Other languages
English (en)
Norwegian (no)
Other versions
NO20023879L (no
Inventor
Andrew A Wolff
Brent K Blackburn
Hani Naief Sabbah
William Clark Stanley
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Publication of NO20023879D0 publication Critical patent/NO20023879D0/no
Publication of NO20023879L publication Critical patent/NO20023879L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20023879A 2000-02-18 2002-08-15 Partielle fettsyre-oksydasjonsinhibitorer i behandlingen av kongestiv hjertesvikt NO20023879L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18356000P 2000-02-18 2000-02-18
US21990800P 2000-07-21 2000-07-21
PCT/US2001/004887 WO2001060348A2 (en) 2000-02-18 2001-02-15 Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure

Publications (2)

Publication Number Publication Date
NO20023879D0 true NO20023879D0 (no) 2002-08-15
NO20023879L NO20023879L (no) 2002-08-15

Family

ID=26879274

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20023879A NO20023879L (no) 2000-02-18 2002-08-15 Partielle fettsyre-oksydasjonsinhibitorer i behandlingen av kongestiv hjertesvikt

Country Status (17)

Country Link
US (2) US6528511B2 (zh)
EP (2) EP1259230A2 (zh)
JP (1) JP2004505886A (zh)
KR (1) KR20020075801A (zh)
CN (1) CN1227004C (zh)
AR (1) AR033510A1 (zh)
AU (1) AU778203B2 (zh)
BR (1) BR0108452A (zh)
CA (1) CA2398691A1 (zh)
HK (1) HK1048250A1 (zh)
IL (1) IL151014A0 (zh)
MX (1) MXPA02007639A (zh)
NO (1) NO20023879L (zh)
NZ (1) NZ520780A (zh)
TW (1) TWI235655B (zh)
WO (1) WO2001060348A2 (zh)
ZA (1) ZA200206451B (zh)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1048250A1 (zh) * 2000-02-18 2003-03-28 Cv Therapeutics, Inc. 在治疗充血性心力衰竭中使用的部分脂肪酸氧化抑制剂
WO2003037323A2 (en) * 2001-10-26 2003-05-08 MEDIGENE AG Gesellschaft für Molekularbiologische Kardiologie und Onkologie Inhibitors of the fatty acid oxidation for prophylaxis and treatment of diseases related to mitochondrial dysfunction
US8460693B2 (en) * 2001-11-08 2013-06-11 Atrium Medical Corporation Intraluminal device with a coating containing synthetic fish oil and a therapeutic agent
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
WO2003099281A2 (en) * 2002-05-21 2003-12-04 Cv Therapeutics, Inc. Administration of a partial fatty acid inhibitor such as ranolazine for the treatment of diabetes
AU2003300827B2 (en) * 2002-12-05 2009-08-13 Gilead Palo Alto, Inc. Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
AU2004303882A1 (en) * 2003-12-18 2005-07-07 Gilead Palo Alto, Inc. 1-akan-2-ol substituted piperazine and piperidine compounds
CA2564679C (en) † 2004-03-22 2015-06-23 Osiris Therapeutics, Inc. Mesenchymal stem cells and uses therefor
US9000040B2 (en) * 2004-09-28 2015-04-07 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US8367099B2 (en) 2004-09-28 2013-02-05 Atrium Medical Corporation Perforated fatty acid films
US20090011116A1 (en) * 2004-09-28 2009-01-08 Atrium Medical Corporation Reducing template with coating receptacle containing a medical device to be coated
US9801982B2 (en) * 2004-09-28 2017-10-31 Atrium Medical Corporation Implantable barrier device
US8124127B2 (en) * 2005-10-15 2012-02-28 Atrium Medical Corporation Hydrophobic cross-linked gels for bioabsorbable drug carrier coatings
US8312836B2 (en) 2004-09-28 2012-11-20 Atrium Medical Corporation Method and apparatus for application of a fresh coating on a medical device
WO2007011385A2 (en) 2004-09-28 2007-01-25 Atrium Medical Corporation Heat cured gel and method of making
US20060083768A1 (en) * 2004-09-28 2006-04-20 Atrium Medical Corporation Method of thickening a coating using a drug
US8263102B2 (en) * 2004-09-28 2012-09-11 Atrium Medical Corporation Drug delivery coating for use with a stent
US9012506B2 (en) * 2004-09-28 2015-04-21 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
JP2008519770A (ja) * 2004-11-09 2008-06-12 シーブイ・セラピューティクス・インコーポレイテッド 心不全の処置における左室リモデリングを逆転させるための少なくとも１種のリモデリング物質と併用するラノラジンの使用
EP1865945A4 (en) * 2005-03-11 2008-05-21 Hong Kong Nitric Oxide Ltd TREATMENT COMBINATION FOR ENDOTHELIAL DISORDERS, ANGINA AND DIABETES
US9278161B2 (en) 2005-09-28 2016-03-08 Atrium Medical Corporation Tissue-separating fatty acid adhesion barrier
US9427423B2 (en) * 2009-03-10 2016-08-30 Atrium Medical Corporation Fatty-acid based particles
US7606617B2 (en) * 2006-01-31 2009-10-20 Cardiac Pacemakers, Inc. Urinalysis for the early detection of and recovery from worsening heart failure
US7875017B2 (en) * 2007-04-11 2011-01-25 Henry Ford Health System Cardiac repair, resizing and reshaping using the venous system of the heart
US9782258B2 (en) * 2006-09-08 2017-10-10 The Regents Of The University Of California Intramyocardial patterning for global cardiac resizing and reshaping
US9492596B2 (en) * 2006-11-06 2016-11-15 Atrium Medical Corporation Barrier layer with underlying medical device and one or more reinforcing support structures
WO2008057344A2 (en) * 2006-11-06 2008-05-15 Atrium Medical Corporation Coated surgical mesh
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
JP2010518169A (ja) * 2007-02-13 2010-05-27 ギリアード・パロ・アルト・インコーポレイテッド 心血管疾患の処置のためのラノラジンの使用
US20080193530A1 (en) * 2007-02-13 2008-08-14 Brent Blackburn Use of ranolazine for the treatment of non-coronary microvascular diseases
JP2010518170A (ja) * 2007-02-13 2010-05-27 ギリアード・パロ・アルト・インコーポレイテッド 冠微小血管疾患の処置のためのラノラジンの使用
WO2008116083A1 (en) * 2007-03-22 2008-09-25 Cv Therapeutics, Inc. Use of ranolazine for elevated brain-type natriuretic peptide
KR20100033490A (ko) * 2007-05-31 2010-03-30 질레드 팔로 알토 인코포레이티드 상승된 뇌-형 나트륨이뇨 펩티드에 대한 라놀라진
CN101066253B (zh) * 2007-06-07 2011-01-05 北京本草天源药物研究院 一种雷诺嗪缓释片
WO2008154033A2 (en) * 2007-06-11 2008-12-18 Symphony Medical, Inc. Cardiac patterning for improving diastolic function
US20090012103A1 (en) 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds
EA201070914A1 (ru) * 2008-02-06 2011-04-29 Гайлид Сайэнсиз, Инк. Применение ранолазина для лечения боли
CA2761771A1 (en) * 2009-05-14 2010-11-18 Gilead Sciences, Inc. Ranolazine for the treatment of cns disorders
US20110038910A1 (en) 2009-08-11 2011-02-17 Atrium Medical Corporation Anti-infective antimicrobial-containing biomaterials
WO2011036677A2 (en) * 2009-09-25 2011-03-31 Lupin Limited Sustained release composition of ranolazine
WO2012009707A2 (en) 2010-07-16 2012-01-19 Atrium Medical Corporation Composition and methods for altering the rate of hydrolysis of cured oil-based materials
ES2414384T3 (es) * 2011-05-11 2013-07-19 Ratiopharm Gmbh Composición de liberación modificada que comprende ranolazina
US9867880B2 (en) 2012-06-13 2018-01-16 Atrium Medical Corporation Cured oil-hydrogel biomaterial compositions for controlled drug delivery
CN104758265B (zh) * 2014-01-07 2019-05-17 四川海思科制药有限公司 一种雷诺嗪缓释片药物组合物及其制备方法
FR3060567B1 (fr) 2016-12-19 2019-05-24 Ecole Normale Superieure De Lyon Substrat de glycosidase fluorogene et procede de detection associe
CN112438955A (zh) * 2019-08-30 2021-03-05 深圳翰宇药业股份有限公司 一种雷诺嗪缓释组合物及其制备方法
GR1010510B (el) * 2022-06-07 2023-07-20 Ελπεν Α.Ε. Φαρμακευτικη Βιομηχανια, Στερεες φαρμακοτεχνικες μορφες παρατεταμενης αποδεσμευσης ρανολαζινης

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4567264A (en) 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US5001193A (en) 1988-12-22 1991-03-19 American Cyanamid Epoxy adhesive for bonding of automotive parts made from bulk or sheet molding compound containing polymeric toughening agent and Mannich Base
ES2091211T3 (es) 1989-06-23 1996-11-01 Syntex Inc Ranolazina y piperazinas relacionadas utilizadas en el tratamiento de tejidos que sufren una lesion fisica o quimica.
US5455045A (en) 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
US6083532A (en) 1995-03-01 2000-07-04 Duramed Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers and tablet formed therefrom
US6303607B1 (en) 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
HK1048250A1 (zh) * 2000-02-18 2003-03-28 Cv Therapeutics, Inc. 在治疗充血性心力衰竭中使用的部分脂肪酸氧化抑制剂
WO2001062744A2 (en) * 2000-02-22 2001-08-30 Cv Therapeutics, Inc. Substituted piperazine compounds

Also Published As

Publication number Publication date
WO2001060348A2 (en) 2001-08-23
EP2033633A2 (en) 2009-03-11
CN1420766A (zh) 2003-05-28
ZA200206451B (en) 2003-12-31
NO20023879L (no) 2002-08-15
AU778203B2 (en) 2004-11-25
HK1048250A1 (zh) 2003-03-28
JP2004505886A (ja) 2004-02-26
IL151014A0 (en) 2003-02-12
US20030119718A1 (en) 2003-06-26
BR0108452A (pt) 2003-04-01
MXPA02007639A (es) 2004-08-23
US6528511B2 (en) 2003-03-04
TWI235655B (en) 2005-07-11
AU4150501A (en) 2001-08-27
WO2001060348A3 (en) 2002-01-31
US6677342B2 (en) 2004-01-13
AR033510A1 (es) 2003-12-26
CA2398691A1 (en) 2001-08-23
EP1259230A2 (en) 2002-11-27
NZ520780A (en) 2006-04-28
US20010047000A1 (en) 2001-11-29
CN1227004C (zh) 2005-11-16
KR20020075801A (ko) 2002-10-05
EP2033633A3 (en) 2009-07-08

Similar Documents

Publication Publication Date Title
NO20023879L (no) Partielle fettsyre-oksydasjonsinhibitorer i behandlingen av kongestiv hjertesvikt
NO20031784D0 (no) Heteroarylalkylpiperazinderivater som fettsyre- oksydasjonsinhibitorer
DE60031710D1 (de) Fettsäurederivat zur behandlung von externen sekretionsstörungen
NO20030249L (no) Oksygenerte estere av 4-jod-fenylamino-benzohydroksamsyrer
NO20033304L (no) Essensielle N-3 fettsyrer i kardialinsuffisiens- og hjertesviktterapi
ATE350375T1 (de) 17beta-hydroxysteroid dehydrogenase type 3 inhibitoren zur behandlung von androgen- abhängigen erkrankungen
EE200200203A (et) Südame arütmia ravis kasutatavad uued oksabispidiinühendid
NO20026008L (no) Fremgangsmåte for behandling av cardiovaskul¶re sykdommer
ATE546425T1 (de) Herstellung von (r)-2-alkyl-3-phenylpropionsäuren
ATE338027T1 (de) Herstellung von iminodiessigsäure-derivaten aus monoethanolamin-substraten
NO20030295L (no) Anvendelse av derivater av valproinsyre- og 2- valproensyreamider for behandling av manier ved bipolare lidelser
ATE469886T1 (de) 17beta-hydroxysteroid dehydrogenase typ-3 hemmer zur behandlung von androgen abhängigen erkrankungen
DE602004022034D1 (de) Herstellung von konjugierten linolsäuren und linolsäuresalzen
NO20024488D0 (no) Anvendelse av melkesyrebakterier for behandling av bukhinnebetennelse
DE60143052D1 (de) Lipid vom carbonsäuretyp
NO20024236L (no) Behandling av psoriasis
DE60120990D1 (de) Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen
DE60042161D1 (de) Ppar delta-inhibitoren zur behandlung kardiovasculärer erkrankungen
DE60124516D1 (de) Kombination des lezithins mit ascorbinsäure
DE60010725D1 (de) Herstellung von arylcarbonsäureestern
DE69934336D1 (de) Verwendung von halofuginone zur behandlung von urethralstriktur
DE60117846D1 (de) Herstellung von 6-aminocaprinsäurealkylestern
DE50012694D1 (de) Verwendung von fettsäurealkanolaminestern
DE60125035D1 (de) Behandlung von plasmid-haltigen lösungen
ATE261965T1 (de) Bispidin-derivate zur behandlung von herzarrhythmien

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application